Monopar Announces Update From Its Currently Enrolling Multi-Center Open-Label Phase 1b Clinical Trial Of Camsirubicin
Portfolio Pulse from Benzinga Newsdesk
Monopar Therapeutics announced an update from its ongoing Phase 1b clinical trial of Camsirubicin, with a patient experiencing tumor shrinkage and successful resection after treatment. All three patients in the 520 mg/m2 cohort achieved stable disease.
June 01, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Monopar Therapeutics' ongoing Phase 1b clinical trial of Camsirubicin showed positive results, with tumor shrinkage, successful resection, and stable disease in all patients in the 520 mg/m2 cohort.
The positive update from Monopar Therapeutics' Phase 1b clinical trial of Camsirubicin indicates that the drug is showing promising results in treating patients. This news is likely to have a positive impact on the company's stock price in the short term, as it demonstrates progress in the development of their product and potential future revenue streams.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100